Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia - Wikidata - awgldk - TriplyDB

Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia

Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia

http://www.wikidata.org/entity/Q35096240

about

Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51 Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.Histone Deacetylase Inhibitors Target the Leukemic Microenvironment by Enhancing a Nherf1-Protein Phosphatase 1α-TAZ Signaling Pathway in Osteoblasts The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.Histone deacetylases 1 and 2 cooperate in regulating BRCA1, CHK1, and RAD51 expression in acute myeloid leukemia cells.Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments.Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.Chemotherapy Options for Poor Responders to Neoadjuvant Chemotherapy for Orbital Granulocytic Sarcoma.Metabolic changes in rat serum after administration of suberoylanilide hydroxamic acid and discriminated by SVM.Selective histone deacetylase small molecule inhibitors: recent progress and perspectives.The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias.Coexpression of Multiple ABC-Transporters is Strongly Associated with Treatment Response in Childhood Acute Myeloid Leukemia.Vorinostat(SAHA) Promotes Hyper-Radiosensitivity in Wild Type p53 Human Glioblastoma Cells.Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabine.A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.Complete molecular remission in relapsed and refractory acute myeloid leukaemia with MLL-AF9 treated with chidamide-based chemotherapy.Epigenetic Regulators in the Development, Maintenance, and Therapeutic Targeting of Acute Myeloid Leukemia.Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.

P2860

Q28396209-B7FBCDFF-A853-4EC9-BE0C-1DF477028A0A Q28535006-884D7BA9-58E1-4964-BA7B-ECD1D216D3F7 Q33983255-020CD7A1-2525-4E20-9939-CF96C90D654B Q34817365-2D4DDC70-971D-46AB-96CE-0E5B2ACF9250 Q35327711-F726F479-C111-42B4-B176-28A68ED66510 Q35546759-9C5F7D80-FE71-4D3B-BB0F-83598B5BDA97 Q36242646-1DFD0D28-4A19-4EDA-873C-9FB4FFC9DA90 Q36444091-CDA3FBC5-94D8-4E34-8978-D2B80215E035 Q36876973-ABECFBB8-8668-40EF-B6AD-18064BEAC5E7 Q37701599-C6476C8B-498C-4FDB-92EE-5B4764E83BCC Q38155455-9389A56A-684F-4FD3-9AA2-1BD2124DD787 Q38572855-CA760735-3885-427C-B672-7C880B8253C0 Q38864977-6E0BDA2E-D480-4241-BC7E-1E88C562DB52 Q39022755-716A6401-EF5D-49B8-8E2C-16E81605CA27 Q39062353-386EEB97-B1E9-4272-B52F-D0C85E7DFCFD Q39954100-7D798833-6824-40FE-94A4-C70B9B0CB2DC Q41172549-D5DCFC84-A456-4BC2-92F0-3E72BD38DBA0 Q42974434-7ECBA3EC-F760-458F-A66D-430D979CC8A5 Q49167307-BD0933B0-D4B6-42B8-B9B3-8FF5DC6A94D1 Q52641884-77FBA7EA-3AB8-4710-9A26-ED655FA2DD1D Q52764678-EC287285-317D-439D-B280-1829CC36550F Q55433291-BE0557E3-6E8F-4946-BBE2-3E2404F6228A Q55447998-49214C85-5DB4-440C-83CF-A1CDC4C65575

P2860

Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia

http://www.wikidata.org/entity/Q35096240

description

2013 nî lūn-bûn

@nan

2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Translational phase I trial of ...... gh-risk acute myeloid leukemia

@ast

Translational phase I trial of ...... gh-risk acute myeloid leukemia

@en

type

label

Translational phase I trial of ...... gh-risk acute myeloid leukemia

@ast

Translational phase I trial of ...... gh-risk acute myeloid leukemia

@en

prefLabel

Translational phase I trial of ...... gh-risk acute myeloid leukemia

@ast

Translational phase I trial of ...... gh-risk acute myeloid leukemia

@en

P1433

Q35096240-46BBB959-FCFE-40B1-958B-1DD5D904C4A1

P1476

Q35096240-EE3ADC14-256F-455B-BEC9-3895EB5EBA02

P2093

Q35096240-082D8253-CCCE-46E5-8124-3D74503944B6

Q35096240-0AEB9C0D-D023-46CE-9F46-85E209852804

Q35096240-0B3678DB-02EA-49A6-9BF2-39C80849DFF7

Q35096240-16FEA2B6-C424-4ED8-86F4-B33B5CB29384

Q35096240-33133DBC-2103-4B10-9C3B-E2B278196B63

Q35096240-40C3A0A0-4CC9-4BC3-B07F-1B11B68CC6F8

Q35096240-48B48B25-5728-451F-8783-00CED541FF24

Q35096240-7754FD48-5A30-42A6-B5AF-57C8E29D7EC1

Q35096240-A06FCF72-4194-4B9D-99B7-2A82371C77C5

Q35096240-BF1CB648-BA6E-4D2F-9002-02C8E370081C

P2860

Q35096240-078B5E0F-16B3-4A16-8A0D-2FA7739EE3FF

Q35096240-0DDF61D0-B654-4605-B92B-5E8AFDFFB623

Q35096240-2078DA11-DFA2-431C-9671-628D095F3060

Q35096240-220FC797-569F-4D9D-BD2E-12AC008EA97F

Q35096240-26F686BE-89EA-4425-AFEA-1052B1594587

Q35096240-2C66017D-B443-41E1-8809-0C4B2AAF7E0A

Q35096240-3BD75C4F-3FE4-4EE1-9676-0E4D3660DDEB

Q35096240-3CEDB8B8-6C02-4292-8EC0-0D35FA9D9956

Q35096240-4329A6D7-B676-4283-851C-C7B9E6EE627D

Q35096240-486C8D2D-9AA3-45D2-AF07-4CBC3461ABDE

P304

Q35096240-5522CAFD-6E49-4C85-844B-D1E04D4094BB

P31

Q35096240-14C2C462-0869-4C02-B267-1806011F7F83

P356

Q35096240-4629EFC5-71E1-45EC-9B63-FD09155C0526

P407

Q35096240-CEE7B18C-F37B-4B40-9D77-20BB482C3EC8

P433

Q35096240-7EE9567A-D97B-4AAE-BE1C-44E68D0016B6

P478

Q35096240-292E5D45-A519-4C12-AA6E-3FBAACB2F75C

P577

Q35096240-7FC61633-F169-4938-9BAE-F1E7C5038400

P698

Q35096240-22603B65-F8FE-4553-9CEA-8B3AA023EA72

P921

Q35096240-80F0250F-A91E-4CCA-9076-EAE354517F24

Q35096240-E500E09D-8A92-4B23-8545-0591CB3E2014

P932

Q35096240-72C8D61A-E97D-4739-AD6E-E15CAB30616D

P356

1078-0432.CCR-12-3165

P1433

Clinical Cancer Research

P1476

Translational phase I trial of ...... gh-risk acute myeloid leukemia

@en

P2093

Bean N Anyang

http://www.w3.org/2001/XMLSchema#string

Douglas D Ross

http://www.w3.org/2001/XMLSchema#string

France Carrier

http://www.w3.org/2001/XMLSchema#string

Hong-Bin Fang

http://www.w3.org/2001/XMLSchema#string

Igor Espinoza-Delgado

http://www.w3.org/2001/XMLSchema#string

Ivana Gojo

http://www.w3.org/2001/XMLSchema#string

Jan H Beumer

http://www.w3.org/2001/XMLSchema#string

Maria R Baer

http://www.w3.org/2001/XMLSchema#string

Mariola Sadowska

http://www.w3.org/2001/XMLSchema#string

Ming Tan

http://www.w3.org/2001/XMLSchema#string

P2860

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells.

A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.

Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.

Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells.

Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.

P304

1838-1851

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-3165

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23403629

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4332848

http://www.w3.org/2001/XMLSchema#string